Advisor Group’s Outlook Therapeutics OTLK Stock Holding History

Advisor Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-31	Closed	-$5K	–	5325
2019 Q1	$5K	Buy	+31	New	+$4.38K	﹤0.01%	4698

Other funds holding OTLK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisor Group's OTLK Position: Q2 2019 in Review

Advisor Group sold out of Outlook Therapeutics (OTLK) in Q2 2019, closing a stake of 31 shares — an estimated $5K sold.

Advisor Group first reported a position in OTLK in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 14 funds tracked by Wall St. Rank hold OTLK as of Q2 2019.

Advisor Group reported no remaining Outlook Therapeutics position as of Q2 2019 after selling out during the quarter.
Advisor Group sold 31 Outlook Therapeutics shares in Q2 2019, an estimated $5K.
Advisor Group first reported a position in Outlook Therapeutics in Q1 2019 and held it in 1 quarter.
Advisor Group's Outlook Therapeutics position peaked at $5K in Q1 2019.
14 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.